Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
63 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Idiopathic (Essential) Hypertension - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Idiopathic (Essential) Hypertension - Pipeline Review, H2 2014', provides an overview of the Idiopathic (Essential) Hypertension's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Idiopathic (Essential) Hypertension and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Idiopathic (Essential) Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Idiopathic (Essential) Hypertension pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Idiopathic (Essential) Hypertension Overview 7 Therapeutics Development 8 Pipeline Products for Idiopathic (Essential) Hypertension - Overview 8 Pipeline Products for Idiopathic (Essential) Hypertension - Comparative Analysis 9 Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 10 Idiopathic (Essential) Hypertension - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Idiopathic (Essential) Hypertension - Products under Development by Companies 15 Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 16 Eli Lilly and Company 16 Daiichi Sankyo Company, Limited 17 Merck & Co., Inc. 18 Novartis AG 19 Actelion Ltd 20 Forest Laboratories, Inc. 21 Les Laboratoires Servier SAS 22 Bayer AG 23 Ahn-Gook Pharmaceutical Co., Ltd. 24 PhaseBio Pharmaceuticals, Inc. 25 Lee's Pharmaceutical Holdings Limited 26 Idiopathic (Essential) Hypertension - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 32 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 (nebivolol + valsartan) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 (perindopril + amlodipine besilate) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 (sacubitril + valsartan) - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 carvedilol - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 (nifedipine + candesartan cilexetil) - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 (losartan potassium + hydrochlorothiazide + amlodipine besylate) - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 CS-3150 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 rostafuroxin - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 ACT-280778 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 LY-2623091 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 PB-1046 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 PB-1120 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Idiopathic (Essential) Hypertension - Recent Pipeline Updates 55 Idiopathic (Essential) Hypertension - Dormant Projects 60 Idiopathic (Essential) Hypertension - Product Development Milestones 61 Featured News & Press Releases 61 Jun 12, 2013: Lee's Pharma Enrolls First Patient In Phase IIb Clinical Trial Of Rostafuroxin In Italy 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 63 Disclaimer 63
List of Tables Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2014 8 Number of Products under Development for Idiopathic (Essential) Hypertension - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H2 2014 16 Idiopathic (Essential) Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 17 Idiopathic (Essential) Hypertension - Pipeline by Merck & Co., Inc., H2 2014 18 Idiopathic (Essential) Hypertension - Pipeline by Novartis AG, H2 2014 19 Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H2 2014 20 Idiopathic (Essential) Hypertension - Pipeline by Forest Laboratories, Inc., H2 2014 21 Idiopathic (Essential) Hypertension - Pipeline by Les Laboratoires Servier SAS, H2 2014 22 Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H2 2014 23 Idiopathic (Essential) Hypertension - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2014 24 Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2014 25 Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 26 Assessment by Monotherapy Products, H2 2014 27 Assessment by Combination Products, H2 2014 28 Number of Products by Stage and Target, H2 2014 31 Number of Products by Stage and Mechanism of Action, H2 2014 34 Number of Products by Stage and Route of Administration, H2 2014 36 Number of Products by Stage and Molecule Type, H2 2014 38 Idiopathic (Essential) Hypertension Therapeutics - Recent Pipeline Updates, H2 2014 55 Idiopathic (Essential) Hypertension - Dormant Projects, H2 2014 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
